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Abstract
Post-operative atrial fibrillation/flutter (PoAF) commonly complicates cardiac surgery, occurring
in 25–60% of patients. PoAF is associated with significant morbidity, higher long-term mortality,
and increased healthcare costs. Novel preventive therapies are clearly needed. In experiments and
short-term trials, seafood-derived long-chain omega-3 polyunsaturated fatty acids (PUFA)
influence several risk factors that might reduce risk of PoAF. A few small and generally
underpowered trials have evaluated effects of omega-3-PUFA supplementation on PoAF, with
mixed results. The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation
(OPERA) trial is an appropriately powered, investigator-initiated, randomized, double-blind,
placebo-controlled, multinational trial to determine whether peri-operative oral omega-3-PUFA
reduces occurrence of PoAF in 1,516 patients undergoing cardiac surgery. Additional aims include
evaluation of resource utilization, biologic pathways and mechanisms, postoperative cognitive
decline, and safety. Broad inclusion criteria encompass a real-world population of outpatients and
inpatients scheduled for cardiac surgery. Treatment comprises a total pre-operative loading dose of
8–10 g of omega-3-PUFA or placebo divided over 2–5 days, followed by 2 g/d until hospital
discharge or post-operative day 10, whichever first. Based on anticipated 30% event rate in
controls, total enrollment of 1,516 patients (758 per treatment arm) will provide 90% power to
detect 25% reduction in PoAF. OPERA will provide invaluable evidence to inform biologic
pathways, proof-of-concept that omega-3-PUFA influence cardiac arrhythmias, and potential
regulatory standards and clinical use of this simple, inexpensive, and low-risk intervention to
prevent PoAF.
INTRODUCTION
Post-operative atrial fibrillation or flutter (PoAF) commonly complicates cardiac surgery,
occurring in 25–60% of all patients, depending on underlying patient characteristics and
methods of arrhythmia ascertainment.1–6 PoAF can produce hemodynamic instability or
symptoms requiring cardioversion or pressor support, and is associated with greater
infectious, renal, and neurological complications.3 PoAF may necessitate in-hospital and/or
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tlong-term antiarrhythmic and anticoagulant drug treatment, potentially increasing risk of
bleeding complications and medication side effects. Patients with persistent PoAF often
suffer from decreased exercise tolerance and fatigue, may undergo recurrent cardioversion
attempts, and have increased long-term mortality.4, 5 Excess mortality appears attributable to
more frequent embolic stroke,6 suggesting a potentially direct causal relationship to PoAF.
PoAF also substantially increases healthcare costs and utilization. Patients with PoAF spend
~0.5 more days in intensive care units and 2–4 more days in the hospital.1, 7 In one analysis,
~$6,400 excess inhospital costs were attributable to each patient developing PoAF.8 Use of
drugs including beta-blockers and amiodarone can partly reduce risk of PoAF, but even
using such medications, 25% or more of patients develop PoAF.9 New therapies to prevent
PoAF and its complications could have considerable health and economic benefits.
Intake of fish or fish oil appears to reduce risk of coronary death, perhaps through reduction
of primary ventricular arrhythmias.10 Experimental evidence supports direct and indirect
antiarrhythmic effects of long-chain omega-3 polyunsaturated fatty acids (PUFA) in fish oil,
eicosapentaenoic acid (EPA/20:5n-3) and docosahexaenoic acid (DHA/22:6n-3), especially
in the setting of acute ischemia. Effects on other cardiac arrhythmias, such as AF, are less
well-established. In experimental studies and short-term clinical trials, omega-3-PUFA
influence several risk factors that might reduce AF,10 but small trials of omega-3-PUFA
supplementation and PoAF have shown mixed results.11–14 The Omega-3 Fatty Acids for
Prevention of Post-operative Atrial Fibrillation (OPERA) trial is an investigator-initiated
study to determine in an appropriately powered, randomized, double-blind, placebo-
controlled, multinational clinical trial whether peri-operative administration of oral
omega-3-PUFA reduces occurrence of PoAF after cardiac surgery.
RATIONALE: OMEGA-3 PUFA AND ATRIAL FIBRILLATION
Experimental Evidence (see Appendix for citations in this section)
In laboratory experiments, omega-3-PUFA modulate function of myocardial Na+ and L-type
Ca++ channels, decreasing myocyte excitability and cytosolic calcium fluctuations.
Omega-3-PUFA also terminate induced asynchronous contractile activity of cultured atrial
myocytes and, in animal studies, reduce experimentally-induced AF while normalizing atrial
connexin levels. Thus, omega-3-PUFA could have direct anti-arrhythmic effects, although
evidence for such effects has been mixed in trials of ambulatory patients with paroxysmal
clinical arrhythmias.
Omega-3-PUFA could also reduce PoAF through other biologic pathways. In animal-
feeding studies, omega-3-PUFA reduce peripheral vascular resistance and left ventricular
hypertrophy, lower workload-specific myocardial oxygen consumption, improve post-
ischemia-reperfusion contractile recovery, and enhance ventricular diastolic function. In
human trials, omega-3-PUFA supplementation lowers resting heart rate and blood pressure,
attenuates vasoconstrictive responses to angiotensin-II, improves arteriolar compliance, and
improves ventricular diastolic filling. Omega-3-PUFA may also favorably affect heart rate
variability and baroreceptor reflex responses, suggesting modulation of balance of
sympathetic versus parasympathetic control mechanisms. Omega-3-PUFA also have anti-
inflammatory effects. Normalization of perturbations in each of these pathways could reduce
PoAF.
Epidemiologic Evidence
In one prospective observational study, individuals who consumed fish more frequently had
higher plasma phospholipid EPA+DHA and significantly lower incidence of AF during
follow-up.15 Among patients followed post-myocardial infarction, higher omega-3-PUFA
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tconsumption was associated with 81% lower risk of AF.16 In another prospective cohort,
higher plasma DHA levels were associated with lower incident AF.17 Conversely, three
other observational studies did not see associations between fish or EPA+DHA consumption
and AF risk.10 Overall, these studies provide some evidence, albeit mixed, that omega-3-
PUFA may reduce new-onset AF among ambulatory individuals.
Trial Evidence
Four small clinical trials have evaluated whether omega-3-PUFA reduces PoAF. In an open-
label (nonblinded) single-center trial (n=160), omega-3-PUFA (2 g/d initiated at least 5 days
pre-operatively, continued until hospital discharge) reduced PoAF (15.2% vs. 33.3%,
p=0.009) and hospital length-of-stay.11 In a placebo-controlled, double-blind trial (n=102)
intravenous omega-3-PUFA (100 mg/d per kg body weight initiated at hospital admission,
continued until ICU discharge) significantly reduced PoAF (17.3% vs. 30.6%; p<0.05) and
hospital length-of-stay.12 Conversely, two other placebo-controlled, double-blind trials
(n=108, n=260) showed no significant effects of peri-operative oral omega-3-PUFA on
PoAF.13, 14 In ambulatory patients with preexisting AF, omega-3-PUFA had no effect on
recurrent AF,18 although relevance of these results to PoAF is unclear given differing
pathophysiology of post-operative vs. recurrent ambulatory arrhythmias.
The mixed findings of these generally small and underpowered trials limit strong
conclusions. Experimental, epidemiologic, and preliminary clinical evidence for potential
benefits, as well as excess morbidity, mortality, and costs associated with PoAF, renders
imperative the rigorous evaluation of whether omega-3-PUFA reduces PoAF in an
appropriately designed, adequately powered clinical trial.
Dosing
Prior studies suggest potential efficacy of modest peri-operative doses. Observational studies
and randomized trials suggest that omega-3-PUFA prevent ventricular arrhythmias at low
doses, e.g., 250–500 mg/d EPA+DHA.10 Similar low dietary doses were associated with
lower incidence of AF among ambulatory adults.15 Supplementation alters circulating and
tissue levels of EPA and DHA within days;19 and in one small trial, a 10 g loading dose over
5 days pre-operatively followed by 2 g/d postoperatively reduced PoAF.11 Because
omega-3-PUFA persist in tissues for several days, a loading dose also provides some buffer
in patients who might not tolerate oral medications for several days post-surgery. Higher
doses (e.g., 5+ g/d) could increase patient dyspepsia and potential concern among treating
physicians for bleeding risk (although bleeding concerns are not supported by studies to-
date; see below).
STUDY DESIGN
Aims
Our primary aim is to determine in a randomized, double-blind, placebo-controlled clinical
trial whether peri-operative oral omega-3-PUFA reduces occurrence of PoAF following
cardiac surgery. Secondary aims include investigation of (a) effects of omega-3-PUFA on
resource utilization; (b) biologic pathways related to PoAF, and effects of omega-3-PUFA
on these pathways; and (c) biologic pathways related to, and effects of omega-3-PUFA on,
post-operative cognitive decline.
Population
OPERA is a multi-center, multi-country (United States, Italy, Argentina) clinical trial
(ClinicalTrials.gov=NCT00970489). Overarching design principles include simplicity and
generalizability to maximize application to “real-world” patients and clinical care. Inclusion
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tcriteria are broad (Table 1) to produce a general population of outpatients and inpatients
scheduled for cardiac surgery. Neither history of prior AF nor planned AF ablation
procedures are exclusions, given similar or higher risk of PoAF and no known biologic
interaction that would reduce efficacy of omega-3-PUFA in such patients. Use of chronic or
prophylactic anti-arrhythmic drugs is also allowed, as OPERA is intended to determine
whether omega-3-PUFA reduces PoAF when added to current best practice.
Consent and Randomization
All identified potential subjects will be provided sufficient information to make an informed
written decision on consent for participation. The protocol and consent process have been
reviewed and approved by human subjects committees of all participating institutions. The
trial will be conducted according to US and international standards of Good Clinical Practice
(FDA Title 21 part 312, International Conference on Harmonization guidelines), applicable
government regulations, and institutional research policies/procedures. At enrollment, the
central Data Coordinating Center will block-10 randomize patients to receive omega-3-
PUFA versus matched placebo by means of computer-generated numbers, stratified by
enrolling medical center and planned valve surgery (yes/no). All investigators, patients, and
providers will be blinded to treatment assignment.
Intervention
Patients will receive oral omega-3-PUFA or placebo (olive oil) as coated, identical-
appearing capsules (Figure 1). Based on the interval between enrollment and planned
surgery, a total pre-operative loading dose of 10 g will be divided over the longest of 3–5
days (or 8 g over 2 days), including the morning of surgery. Patients enrolled one day prior
to surgery will receive a slightly lower loading dose (8 g in two divided doses) to avoid daily
dosing above the currently approved dose for treatment of hypertriglyceridemia (4 g/d).
Flexibility in pre-operative dosing maximizes generalizability by allowing enrollment of
most patients, including inpatients who are often identified only one day before cardiac
surgery. OPERA excludes patients undergoing emergent surgery, i.e., on the day of
presentation.
Post-operatively, each patient will receive 2 g/d until hospital discharge or post-operative
day 10 (i.e., administrative censoring), whichever occurs sooner. Study drug and follow-up
for PoAF will be discontinued at this timepoint, because most PoAF occurs between post-
operative days 2 to 7, and because the Steering and Events Committees judged that new-
onset AF beyond post-operative day 10 would be difficult to attribute directly to cardiac
surgery and that new-onset AF after hospital discharge would be difficult to capture
systematically. For patients unable to tolerate oral medications postoperatively, the study
drug may be administered via non-PVC nasogastric/gastric tube if present for clinical
indications, or otherwise as soon as the patient is tolerating oral medications, consistent with
OPERA’s design as a trial of both efficacy and effectiveness. Study drug administration will
not be altered by protocol-defined events (e.g., PoAF) due to interest in evaluating both
multiple endpoints and safety outcomes in all patients, except at discretion of the treating
physician or patient due to tolerance or safety concerns. Compliance will be monitored by
capsule count for outpatient loading and by hospital records for inpatients.
With the exception of study drug (omega-3-PUFA or placebo), all other treatments,
including surgical and anesthetic procedures; chronic or prophylactic anti-arrhythmic
medication use; and treatment of arrhythmic episodes; will be entirely at discretion of the
physicians caring for the patient. Current best-practice guidelines for prevention of PoAF
will be strongly recommended to all Centers;20 data will be collected on use of relevant peri-
operative medications/treatments.
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The primary endpoint will be the occurrence of PoAF of at least 30 seconds duration (Table
2). A secondary endpoint will be sustained or symptomatic AF, that may be considered to be
a more clinical endpoint. Additional endpoints will include hospital length-of-stay, 30-day
and 1-year mortality, secondary and safety outcomes, and Ancillary Biologic Studies (see
below).
Centers will be encouraged to utilize continuous cardiac monitoring for at least 5 days post-
surgery and daily in-hospital 12-lead ECGs, whenever possible and according to usual
practice at each Center. Clinical information and confirmatory rhythm strips/12-lead ECGs
will be collected on all postoperative arrhythmias of at least 30 seconds duration, including
AF, other SVT, VT, and VF. Because some patients may experience a brief initial episode of
AF followed by more sustained/symptomatic AF, data on at least the first 3 episodes of AF
will be collected to optimize detection of the secondary AF endpoint while still maintaining
reasonable Center workload.
All AF episodes and other arrhythmia endpoints will be adjudicated by the Events
Committee, comprised of cardiac electrophysiologists blinded to patient treatment
assignment, using prespecified algorithms that make use of clinical information and direct
review of rhythm strips/12-lead ECGs. Thirty-day mortality will be assessed by Center-
based clinic or telephone follow-up, with cause-specific adjudication by the Events
Committee. One-year all-cause mortality will be assessed by Center-based clinic or
telephone follow-up.
Covariates
Standardized data will be collected on demographics; cardiovascular risk factors; major
comorbidities; past medical/surgical history; anthropometry; outpatient and inpatient
medications; baseline laboratory indices; and smoking, physical activity, and dietary habits.
Details of the surgical and anesthetic procedure will be recorded. Daily follow-up
information, including relevant to bleeding outcomes (Table 2), and discharge information
will be recorded.
Biologic and Ancillary Studies
In addition to arrhythmic endpoints, OPERA provides a rich opportunity to investigate
biologic pathways related to PoAF and other surgical complications; and effects of
omega-3-PUFA on these and other risk pathways. Biospecimens will be collected and
centrally stored utilizing standardized procedures and equipment (Figure 2). Multiple time
points will help establish time courses of effects. Multiple tissues (blood, urine, atrium,
pericardial fat) will help establish pathways of effects. Planned analytes include: fatty acid
concentrations in red blood cell membranes, plasma, and atrial tissue; markers of oxidative
stress and inflammation including plasma, urine, and myocardial F2-isoprostanes, urine
leukotriene-E4 and 11-deoxy-thromboxane-B2, and plasma high sensitivity C-reactive
protein and long pentraxin PTX3; markers of myocardial injury/stress including troponinT
and N-terminal proBNP; and markers of neurologic injury including serum neuron-specific
enolase. Cognitive function will be measured in US patients by trained personnel at
enrollment, postoperative day 2, 30-days, and 1-year, using validated, robust cognitive
batteries assessing key domains (e.g., immediate and delayed memory, visuospatial
construction, language, attention).
Statistical Analysis
The primary analysis will be intention-to-treat, including all enrolled subjects in the
analysis. The primary outcome will be the cumulative occurrence (risk) of PoAF, with
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tbetween-group differences evaluated using the binomial test of proportions, two-tailed
alpha=0.05. Between-group AF incidence will be compared using Kaplan-Meier survival
analyses, with significance evaluated by log-rank test. Potential baseline differences
between treatment groups will be evaluated using unpaired Students t-tests (continuous
variables) or chi-square or Fisher exact tests (categorical variables), as appropriate.
Differences in utilization (e.g., length-of-stay) will be evaluated using unpaired Students t-
tests, following transformation to approximate normality if necessary. Secondary analyses
will be performed comparing groups on-treatment (taking active treatment or placebo ≥80%
of intended days); using multivariable logistic regression to adjust for potential confounding
characteristics not accounted for by randomization (any between-group baseline differences
at alpha<0.10); and to assess effects of treatment on number of AF episodes (up to 3).
Subgroup analyses will be performed according to (1) age (≥ vs. <70 years); (2) sex; (3)
surgery (with vs. without cardiac valve repair/replacement); (4) study drug loading period
(4–5 vs. 2–3 days); (5) habitual oily fish consumption (≥ vs. <2 servings/week); (6)
enrollment erythrocyte omega-3-PUFA levels (≥ vs. <median); and (7) receiving vs. not
receiving peri-operative (a) beta-blockers, (b) statins, (c) amiodarone, or (d) ACE-inhibitors/
ARBs. The first patient was enrolled in August 2010, and we expect enrollment to conclude
in Spring 2012 and primary results to be reported by Fall 2012.
Power Calculations
Although PoAF has been reported in 33–60% of surgery patients, modern rates might be
lower due to improved surgical procedures or use of prophylactic medications. OPERA has
the critical strength of adequate power to detect clinically-relevant effects even with modest
event rates. Based on 30% event rate in controls and two-sided alpha=0.05, a total of 1,516
patients (758 per treatment arm) provides 90% power to detect 25% reduction (our primary
power calculation) and 80% power to detect 22% reduction in PoAF. With 35% or 25%
event rate in controls, OPERA will have 90% power to detect 22.5% or 28% reduction,
respectively, and 80% power to detect 20% or 24% reduction, respectively. All power
calculations include anticipated 5% drop-out, a realistic value given brief treatment and in-
hospital primary outcomes.
Safety Evaluation
Multiple safety outcomes will be evaluated based on prespecified definitions and procedures
(Table 2). The Events Committee will adjudicate arrhythmic events and 30-day cause-
specific mortality. Occurrence of major adverse cardiovascular events, bleeding, and other
adverse events (AE) will be assessed. Safety assessment will be based mainly on frequency
and extent of the different AE in each treatment arm. We will evaluate potential interaction
with Class I or III antiarrhythmic drugs in stratified analyses. Other safety data (e.g.,
laboratory/ECG, vital signs, other testing) will be considered post-hoc as appropriate.
AE will be summarized for each treatment group as number and percentage having any AE,
an AE in each body system, and each individual AE; and by extent of bleeding as described
above. Study drug can be temporarily or permanently suspended at any time upon discretion
of the treating physicians. The study period during which AE must be reported is normally
defined as the period from initiation of any study procedures (enrollment) to end of study
drug treatment. We will also collect information on serious AE identified up to 2 weeks
following study drug discontinuation. Every serious AE suspected by local investigators to
be related to study medications will be reported to the Data Coordinating Center within 24
hours of learning of its occurrence. All potential AE will be recorded and reported to the
Steering Committee and an independent Data Safety and Monitoring Board (DSMB).
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Duties related to scientific integrity include review and approval of scientific rationale and
research protocol; evaluation of trial progress, including periodic assessments of data quality
and timeliness, recruitment, accrual and retention, participant risk versus benefit, and
performance of trial sites; consideration of external factors such as scientific or therapeutic
developments that may impact safety, ethics or integrity of the trial; and making of
recommendations and assistance in resolution of problems reported by the Investigators.
Duties related to patient safety include review and approval of research protocol, informed
consent documents, and plans for data and safety monitoring; monitoring of types and rates
of AE; development of plans for, and assessment of results of, interim analyses and stopping
rules, in advance of data analysis; protection of confidentiality of study data and monitoring
results; and making of recommendations to the Steering Committee concerning
continuation, termination, or other trial modifications based on observed beneficial or
adverse effects of the treatment under study.
Bimonthly safety reports will be reviewed by the DSMB, and open or closed sessions held at
the call of the DSMB Chair. One complete interim analysis of efficacy and safety will be
prepared by a statistician not involved in the trial after enrollment of two-thirds of the
patients and reviewed by the DSMB. The study can be stopped at anytime if, in the DSMB’s
judgment, the study participants are subjected to unnecessary risk. The DSMB can also
recommend early termination because of overwhelming evidence of efficacy. Although
conventional O'Brian Flemming boundaries will be examined for the interim analysis, any
decision concerning early termination will be based on a comprehensive assessment of all
available information, weighing both obligations to participants and to society and with clear
recognition of the potential for overestimates of treatment effects (good or bad) that can
arise when a trial is terminated early on the basis of limited numbers of outcomes.
Contemplation of early termination for efficacy will also take into account the potential
adverse effect on the multiple relevant primary, secondary, and biologic endpoints in the
trial.
The modest omega-3-PUFA dose and treatment duration (maximum 2 weeks) should
minimize drug-related serious AE. Smaller prior clinical trials using similar or higher doses
in surgery patients did not report any treatment-related serious AE.11, 21, 22 In a trial among
204 patients undergoing coronary angioplasty, patients received omega-3-PUFA 6 g/d
(starting ~5 days pre-angioplasty, continued for 6 months) without any significant treatment-
related AE or bleeding episodes.23 In a trial among 610 patients undergoing cardiac surgery,
omega-3-PUFA 4 g/d (starting on post-operative day 2, continued for one year), together
with either aspirin or warfarin, did not result in increased clinical bleeding.24
CONCLUSIONS
The OPERA trial will critically assess important research questions in a carefully designed
randomized, double-blind, placebo-controlled, clinical trial. The multi-country, multi-center
collaboration provides a broad cross-section of “real-world” patients, with appropriate
power to detect clinically-relevant effects and facilitate secondary and subgroup analyses.
Prospective evaluation of utilization outcomes will inform potential projected savings of this
novel approach to preventing cardiac surgery complications. Novel ancillary studies will
elucidate important mechanistic pathways for PoAF and cognitive decline and potential
effects of omega-3-PUFA on these pathways. The OPERA trial will provide invaluable
evidence on biologic mechanisms, provide a critical test of the hypothesis that omega-3-
PUFA influence cardiac arrhythmias, and inform potential regulatory standards and clinical
use of this simple, inexpensive, and low-risk intervention to prevent PoAF.
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Dosing of study drug in the OPERA trial.
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Biologic specimen collection in the OPERA trial.
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Table 1
OPERA Inclusion and Exclusion Criteria.
Inclusion Criteria Exclusion Criteria
• Age 18 years or older.
• Scheduled for cardiac surgery on the following day
or later.*
– Sinus rhythm on ECG at enrollment.†
• Regular use (3 or more days per week) of fish oil during the past
4 weeks.
• Known allergy or intolerance to fish oil or olive oil.
• Currently pregnant.
• Planned or existing cardiac transplant or left ventricular assist
device.
• Unable or unwilling to provide informed written consent.
*
Cardiac surgery may include surgical coronary artery bypass, surgical valve repair or replacement, or any other open cardiac surgery that includes
opening of the pericardium, including any combination of the above.
†
Includes sinus bradycardia or tachycardia, with or without ectopic beats. History of prior AF is not an exclusion criterion.
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Table 2
OPERA Endpoints.
Endpoint Definition Characteristics
Atrial Fibrillation *
(primary endpoint)
Any documented atrial fibrillation
(AF) or atrial flutter (AFL) of at
least 30 seconds duration and
documented by rhythm strip or 12-
lead ECG. If only a shorter duration
ECG is available, then the diagnosis
of AF/AFL is based on the
arrhythmia being present at onset or
termination.
• AF - Irregular ventricular response independent of rate, with
the following characteristics:
– QRS complex unchanged from baseline or
functional bundle branch block, and
– absence of P waves, or
– presence of fibrillatory waves in isoelectric
periods of the ECG.
• AFL - With variable block, 2:1, 3:1, or 4:1, but not sinus
tachycardia, with the following characteristics:
– QRS unchanged from baseline or functional
bundle branch block, and
– absence of sinus P waves, and
– presence of flutter waves in isoelectric periods of
the QRS complex of the ECG.
• AF/ AFL (unable to distinguish) - Presence of RR interval
irregularity will favor AF diagnosis.
• SVT/ suspect AF - Paroxysmal SVT not consistent with AFL
or sinus tachycardia, with characteristics of SVT (see below)
except >0.02 second variation in successive cardiac cycles, but
not definite AF.
Sustained or
Symptomatic Atrial
Fibrillation *
(secondary endpoint)
AF/AFL meeting all requirements
for the primary endpoint, plus being
either sustained, symptomatic, or
both.
• Sustained: Presence for at least one hour duration.
• Symptomatic:
– treated with electrical or pharmacological
cardioversion, or
– temporally associated with new or worsening
chest pain or shortness of breath, or
– treated with fluid or pressor treatment for
hypotension (drop in blood pressure requiring
escalation of treatment).
Other Arrhythmias * Other supraventricular tachycardia
(SVT)
• SVT/ suspect not AF - Paroxysmal SVT not consistent with
AFL or sinus tachycardia, with the following characteristics:
– mean ventricular rate ≥ 100 beats per minute, and
– QRS complex unchanged from baseline or
functional bundle branch block, and
– <0.02 second variation in successive cardiac
cycles unless cycle length alternans is seen, and
– no evidence of atrioventricular dissociation, and
– absence of sinus P waves.
Ventricular tachycardia (VT) • Wide complex QRS (>120 msec), rhythm > 100/min, with AV
dissociation, capture or fusion beats.
Ventricular fibrillation (VF) • Completely disorganized ventricular electrical activity.
Utilization Endpoints Unit and hospital length-of-stays • Total intensive/coronary care unit length-of-stay
• Total days of telemetry monitoring
• Total hospital length-of-stay
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Endpoint Definition Characteristics
Mortality and Safety
Endpoints
Mortality • 30-day mortality, including cause-specific mortality: †
– cardiac arrhythmic
– cardiac nonarrhythmic
– vascular
– non-cardiovascular
– unknown
• 1-year mortality, all-cause
Major adverse coronary events
(MACE)
• Myocardial infarction, stroke, and cardiovascular death †
Bleeding • Chest tube output during the first 24 hours after cardiac
surgery.
• Total RBC transfusions from enrollment to hospital discharge
or post-operative day 10 (whichever sooner).
• Any bleeding requiring re-exploration or surgery.
• All other episodes of minor and major bleeding.
• Composite TIMI bleeding indices, including major, minor, and
loss no site bleeding.
Other adverse events and serious
adverse events
• Coded as appropriate using the MedDRA dictionary.
*
From the time of cardiac surgery until hospital discharge or post-operative day 10, whichever occurs first.
†
Standardized definitions, available from the authors upon request.
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